Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Results of Operations
MCK logo

McKesson Revenues Surge 10% to $103.1B Amid Oncology Acquisitions

MCK10-QFiling Date: 11/6/2025
McKesson Corporation
Description

What this story covers

McKesson reported Q2 revenues of 103.1 billion dollars, up 10 percent, driven by pharmaceutical volumes and specialty growth. Key acquisitions in oncology totaled 3.4 billion dollars, boosting segments. Net income hit 1.1 billion dollars, with solid liquidity supporting repurchases and dividends. Opioid liabilities at 5.7 billion dollars managed via settlements; risks stable per filing.

Story snapshot

CompanyMcKesson Corporation
TickerMCK
VariantStandard detailed
Duration11:36
Filing type10-Q
PeriodQ2 2025
IndustryHealthcare & Pharmaceuticals
Accession0000927653-25-000140

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in